The development and pharmacology of proteasome inhibitors for the management and treatment of cancer (Q37709559)

22 August 2017

1 reference

title

The development and pharmacology of proteasome inhibitors for the management and treatment of cancer (English)

1 reference

22 August 2017

1 reference

Bruce Ruggeri

1 reference

22 August 2017

Sheila Miknyoczki

series ordinal

1 reference

22 August 2017

Bruce Dorsey

series ordinal

1 reference

22 August 2017

Ai-Min Hui

series ordinal

1 reference

22 August 2017

language of work or name

1 reference

27 November 2009

1 reference

22 August 2017

published in

Advances in Pharmacology

1 reference

22 August 2017

1 reference

22 August 2017

page(s)

91-135

1 reference

The development of proteasome inhibitors as anticancer drugs

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Rules for ring closure

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Approval summary for bortezomib for injection in the treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Proteasome inhibitor bortezomib for the treatment of multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

The ubiquitin-proteasome proteolytic pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Anti-angiogenic and anti-tumor properties of proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib for myeloma -- much ado about something

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Activation of the cell death program by inhibition of proteasome function

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Structure of 20S proteasome from yeast at 2.4 A resolution

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Epoxomicin, a new antitumor agent of microbial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Targeting the ubiquitin system in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Proteasome inhibitor drugs on the rise

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib for the treatment of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Many facets of bortezomib resistance/susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentr

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Proteasome inhibitors in cancer therapy: lessons from the first decade

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A phase 2 study of bortezomib in relapsed, refractory myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib: proteasome inhibition as an effective anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Signal integration in the endoplasmic reticulum unfolded protein response

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Chemical Genomics Identifies the Unfolded Protein Response as a Target for Selective Cancer Cell Killing during Glucose Deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

The potential of proteasome inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Proteasome inhibition potentiates antitumor effects of photodynamic therapy in mice through induction of endoplasmic reticulum stress and unfolded protein response

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Myeloma bone disease and proteasome inhibition therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Clinical development of novel proteasome inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

1 reference

https://api.crossref.org/works/10.1016%2FS1054-3589%2808%2957003-7

7 January 2021

10.1016/S1054-3589(08)57003-7

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oxmcg52en5hl3fqyfkq7cm43eu

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_oxmcg52en5hl3fqyfkq7cm43eu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/oxmcg52en5hl3fqyfkq7cm43eu

30 July 2022

mapped directly with Wikidata item

https://api.fatcat.wiki/v0/release/oxmcg52en5hl3fqyfkq7cm43eu

1 reference

30 July 2022